At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
ASN51drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Target Occupancy of ASN51 Following Repeated Oral Doses
In Brief
A Phase 1 clinical trial evaluating ASN51 for Healthy. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs), after repeated doses of ASN51 in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
CollaboratorsHammersmith Medicines Research, Invicro
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedFeb 2023
Primary CompletionApr 2023
Study CompletionJun 2023
TodayJul 2026
First PostedFeb 13, 2023
Enrollment StartJan 26, 2023
Primary CompletionApr 4, 2023
Study CompletionJun 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.4 years ago
Interventions
ASN51drug
Oral capsule